Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: working on updating assumption 2 per Sandy's comments
Info
titleInformation for Reviewers

Text in black is part of the template used to create this document and is not under review. Please review the blue text; this text represents the changes made to the template that are specific to this QRS instrument.

Please especially note assumptions 7 through 9, which discuss the concept of "conditional branching," and Example 1, which shows an example of data not done due to conditional branching in the electronic version of the PRO-CTCAE. Conditional branching replaces the concept of logically skipped items as it allows for situations (such as in the electronic version of the PRO-CTCAE) where items can be not done due to conditional branching. In this case NIH provides scoring for those items not done due to conditional branching. Because it is known that the items were not done due to the symptom not occurring (e.g., when the frequency item response is "Never"), any remaining items for the symptom are provided a standardized score of "None" or "Not at all", with a numeric value of 0.

Page properties
Title

Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Library Version 1.0 (PRO-CTCAE V1.0)

CDISC ReferenceQuestionnaireSupplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials
QRS Short Name
Page properties
QuestionnaireSupplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials
Title

Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Library Version 1.0 (PRO-CTCAE V1.0)

CDISC ReferenceQRS Short Name

PRO-CTCAE V1.0

QRS Permission StatusApproved
TeamPancreatic Cancer Therapeutic Area Team and CDISC Questionnaires, CDISC Questionnaires, Ratings, and Scales (QRS) Subteam
Supplement Version1.0
StatusDRAFT
Date20222023-0312-2208
NotesThis supplement is intended to be used with other CDISC user guides for specific therapeutic/disease areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical Trials.
Known Issue
  • The concept of “conditional branching” in QRS instruments is when the instrument directs the subject to another item of the instrument based on the result of a response compare for a given condition. This concept was reviewed with the CDISC standards teams and it was agreed to use this term instead of “logically skipped item” moving forward for this QRS instrument use case. A new QRS variable named “QSCBRFL” with the description of “Conditionally Branched Item Flag” has been approved for SDTMIG v4.0. This new variable will streamline the data representation of conditionally branched items.


Revision History

DateVersion
20222023-0312-22081.0 Draft
Info

The CDISC PRO-CTCAE V1.0 supplement version Version 1.0 was developed based on the NCI/NIH PRO-CTCAE® website. The website’s PRO-CTCAE Version 1.0 Release Notes release notes indicate the revisions made by NCI/NIH on the PRO-CTCAE 1.0 instrumentmeasurement system. The instrument’s measurement system version is 1.0 based on the website's release notes (specific correction of typographical errors in the different CRF translations). NCI/NIH will notify CDISC of any major changes in the future that would require a change control to the CDISC PRO-CTCAE V1.0 supplement version.

© 2022 2023 Clinical Data Interchange Standards Consortium, Inc. All rights reserved. 

1 Introduction

This document describes the CDISC implementation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Item Library Version 1.0 (PRO-CTCAE V1.0) instrument.

CDISC did not modify this questionnaires, ratings, and scales (QRS) instrument measurement to meet Clinical Data Acquisition Standards Harmonization (CDASH) case report form (CRF) standards.

The representation of data collected for this instrument measurement is based on the Study Data Tabulation Model Implementation Guide (SDTMIG) Questionnaires (QS) domain model, which can be found at the CDISC website at: https://www.cdisc.org/standards/foundational/sdtmig.

These specific implementation details for this instrument measurement are meant to be used in conjunction with the SDTMIG. All instrument documentation All QRS documentation can be found on the CDISC web site at: https://www.cdisc.org/standards/foundational/qrs.

The CDISC Intellectual Property Policy can be found on the CDISC website at: https://www.cdisc.org/about/bylaws.

1.1 Representations and Warranties, Limitations of Liability, and Disclaimers

This document is a supplement to the SDTMIG for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material.

CDISC specifies how to structure the data that has been collected in a database, not what should be collected or how to conduct clinical assessments or protocols. CDISC disclaims any liability for your use of this material.

Although the United States Food and Drug Administration (US FDA) has provided input with regard to this supplement, this input does not constitute US FDA endorsement of any particular instrument. 

2 Copyright Status

The NATIONAL CANCER INSTITUTE (NCI) at the NATIONAL INSTITUTES OF HEALTH (NIH) owns the copyright for the PRO-CTCAE V1.0 instrument and has made it exempt from copyright restrictionsThe PRO-CTCAE® Measurement System is owned exclusively by National Cancer Institute (NCI). Use of the PRO-CTCAE V1.0 is subject to NCI terms of use policy listed on the website. Based on these terms of use, CDISC considers this instrument exempt from copyright restrictions. CDISC has included this supplement in the CDISC inventory of QRS data standards supplements. Hence, CDISC developed QSTESTCD and QSTEST for each item based on the actual text on the instrument measurement system

The CDISC documentation of this instrument consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) CRF(s) annotated with the CDISC SDTMIG variables with submission values.

Note: CDISC Controlled Terminology is maintained by NCI Enterprise Vocabulary Services (EVS). The most recent version should be accessed through the CDISC website at: https://www.cdisc.org/standards/terminology/controlled-terminology.

CDISC has developed this documentation at no cost to copyright holder or any additional cost to users of the instrument beyond the normal licenses fees charged by the copyright holder.

CDISC acknowledges Sandra Mitchell, PhD, CRNP, Research Scientist and Program Director Scientific Lead, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Outcomes Research Branch; Healthcare Delivery Research Program Division of Cancer Control and Population Sciences, National Cancer Institute, for the approval to include the PRO-CTCAE V1.0 in the CDISC data standards.

Reference for the PRO-CTCAE V1.0:

  • These materials discuss and/or include the PRO-CTCAE® Item Library Version 1.0 (PRO-CTCAE V1.0). The PRO-CTCAE® Measurement System is owned exclusively by the National Cancer Institute. No part of the PRO-CTCAE® Measurement System may be adapted, altered, amended, abridged, modified, condensed, made into derivative works, or translated without prior written permission from the US National Cancer Institute. PRO-CTCAE is a registered trademark of the US Department of Health & Human Services. All rights reserved. For additional terms of use and to access PRO-CTCAE® Measurement System content, visit https://healthcaredelivery.cancer.gov/pro-ctcae/.
  • The PRO-CTCAE trademark items and information herein were developed by the Division of Cancer Control and Population Sciences in the National Cancer Institute at the National Institutes of Health, Bethesda, Maryland, USA. Use of the PRO-CTCAE is subject to NCI’s Terms of Use. PRO-CTCAE Measurement System content should be downloaded using the Instruments & Form Builder link (https://healthcaredelivery.cancer.gov/pro-ctcae/).

The CDISC documentation of this measurement system consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) CRF(s) annotated with the CDISC SDTMIG variables with submission values (referred to hereafter as annotated Item Library v1.0 form).

Note: CDISC Controlled Terminology is maintained by NCI Enterprise Vocabulary Services (EVS). The most recent version should be accessed through the CDISC website at: https://www.cdisc.org/standards/terminology/controlled-terminology.

CDISC has developed this documentation at no cost to the owner, trademark holder, or users of the measurement system.

CDISC acknowledges Sandra Mitchell, PhD, CRNP, Research Scientist and Program Director Scientific Lead, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Outcomes Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, for the approval to include the PRO-CTCAE V1.0 in the CDISC data standards.

References for the PRO-CTCAE V1.0:

  • Basch E, Reeve BB, Mitchell
  • These materials discuss and/or include the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Item Library Version 1.0 Version Date 4/26/2020 (PRO-CTCAE V1.0) which is owned exclusively by the Division of Cancer Control and Population Sciences in the NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH (NCI). No part of the PRO-CTCAE V1.0 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying recording, or other electronic or mechanical methods, without the prior written permission of NCI and payment of any applicable fees. PRO-CTCAE V1.0 copyright, NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH (NCI). All rights reserved.
  • The PRO-CTCAE trademark items and information herein were developed by the Division of Cancer Control and Population Sciences in the NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE is subject to NCI's "Terms of Use". PRO-CTCAE Measurement System content should be downloaded using the "Instrument & Form Builder". https://healthcaredelivery.cancer.gov/prot-ctcae/. (Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).J Natl Cancer Inst 2014 Sept Sep 29;106(9)).
  • [1] National Institutes of Health – National Cancer Institute, Division of Cancer Control & Population Sciences. (2017, July 2) https://healthcaredelivery.cancer.gov/pro-ctcae/overview.html

3 The QS Domain Model

3.1 Assumptions for the QS Domain Model

All assumptions and business rules described in the SDTMIG QS domain are applicable to this supplement. Additional assumptions specific to the PRO-CTCAE V1.0 are listed below.

The PRO-CTCAE V1.0measurement system is a patient-reported outcome (PRO) instrument developed to capture symptomatic adverse events of patients in cancer clinical trials. The PRO-CTCAE V1.0 was designed to be used in conjunction with the Common Terminology Criteria for Adverse Events (CTCAE).[1] It consists of an item library rather than a static/fixed question item type of instrument. You should . This item library concept is different than other CDISC public domain and copyrighted specific QRS instruments. Users are directed to use the form builder as described on the PRO-CTCAE website to build CRFs and with instructions provided by NCI to select the items to implement it in your a clinical study. The PRO-CTCAE V1.0 includes multiple-choice questions on the frequency, severity, interference, presence/absence, and /or amount of specific adverse events.

Administration of PRO-CTCAE V1.0 may be conducted via different modes, including screen-based, interactive voice response, and paper. Electronic implementation of the PRO-CTCAE V1.0 instrument is measurement system is recommended by NCI/NIH.

  1. As a CDISC QRS standard, the instrument supplement name is PRO-CTCAE V1.0, as provided in this supplementdocument. As an item library, sponsors sponsors may select items from the overall library as a subset of items with the same CDISC Controlled Terminology as appropriate for the condition being studied. It is the users user's responsibility to identify the subset of items used from the overall PRO-CTCAE V1.0 Quick Guide to the Item Library (Version 1.0). The subsetted PRO-CTCAE V1.0 user's instrument measurement system should be titled "PRO-CTCAE sponsor-specified symptoms..." based on the sponsor's discretion when they identify the specific items being used. This will distinctly describe the subsetted instrument measurement system from the overall PRO-CTCAE V1.0. The form builder does not represent the Quick Guide to the Item Library symptom term when creating forms with selected symptoms. Users need to reference the annotated Item Library v1.0 form to obtain the related symptom term for forms based on selected symptoms. 
  2. For the PRO-CTCAE V1.0, QSORRES is populated represented with the text description while ; the numeric rating is represented in the standardized character and numeric result variables QSSTRESC and QSSTRESN. Please reference see the PRO-CTCAE website FAQs for more details on the numeric responsesThe responses for the PRO-CTCAE V1.0 are as follows:
    1. Depending on the symptomatic adverse event (AE) being measured, items assessing symptom presence/absence are rated as follows:Items rated on a binary response scale and rated from 0-1 (e.g(i.e., 0 = “No” and 1 = “Yes”);
    2. Items rated on multiple (more than two) response scale and rated from 0-1 (e.gassessing symptom frequency are rated from 0-4 (i.e., 0 = “No”“Never”, 1 = “Yes”, and “Not applicable” or "Not Applicable"); orItems rated on multiple (more than two) response scale and = “Rarely”, 2 = “Occasionally”, 3 = “Frequently”, and 4 = “Almost constantly”).
    3. Items assessing symptom severity are rated on a 5-point scale rated from 0-1 4 (e.g., 0 = “No”“None”, 1 = “Mild”, 2 = “Yes”, “Not sexually active”, and “Prefer not to answer”“Moderate”, 3 = “Severe”, and 4 = “Very severe”).
    4. Items assessing symptom amount are rated on a 5-point scale and interference are rated from 0-4 (e.g., 0 = “Not at all”, 1 = “A little bit”, 2 = “Somewhat”, 3 = “Quite a bit”, and 4 = “Very much”).
    5. Items assessing symptom frequency are rated on a 5-point scale and amount are rated from 0-4 (e.g., 0 = “Never”“Not at all”, 1 = “Rarely”“A little bit”, 2 = “Occasionally”“Somewhat”, 3 = “Frequently”“Quite a bit”, and 4 = “Almost constantly”, "Not sexually
      active"= “Very much”).
    6. QSTESTCD = "PT01066A " to "PT01071A" sexual symptoms have specific responses.
      1. QSTESTCD=PT01069A and QSTESTCD=PT01070A assessing sexual symptom presence/absence are rated on multiple (more than 2) response scale and rated from 1-0 (e.g., 1 = “Yes” and 0 = “No”, “Not sexually active”, and “Prefer not to answer”).
      Items assessing
      1. QSTESTCD=PT01066A, PT01068A, and PT01071A assessing sexual symptom severity are rated on a 5-point scale

      and are
      1. rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”

      , “Not applicable”
      1. , "Not sexually


      1. active", and “Prefer not to answer”).

      Items assessing symptom interference are
      1. QSTESTCD = "PT01067A" assessing sexual symptom frequency is rated on a 5-point scale
      and are
      1. rated from 0-4 (e.g., 0 =
      “Not at all”
      1. “Never”, 1 =
      “A little bit”
      1. “Rarely”, 2 =
      “Somewhat”
      1. “Occasionally”, 3 =
      “Quite a bit”
      1. “Frequently”,
      and
      1. 4 =
      “Very much”).
  3. The CRF represents up to 5 "other symptoms" to be recorded. In discussions with NIH, it was agreed to provide up to 10 "other symptoms" to be recorded if they existed. QSTESTCDs (QSTESTCDs "PT01082A" thru "PT0191A") and severity of the symptom at its worst (QSTESTCDs "PT01082B" thru "PT0191B").
  4. Total scoring instructions have not yet been developed. Item-level scores are not combined (i.e., No total score nor symptom-specific scores are calculated.).
  5. The time period of evaluation for the PRO-CTCAE V1.0 is populated in the QSEVLINT field in ISO 8601 format when the evaluation interval can be precisely described as duration. The evaluation interval for the PRO-CTCAE V1.0 is the past 7 days (QSEVLINT = "-P7D". Please reference the PRO-CTCAE website for more details on the evaluation interval.
      1. “Almost constantly”, "Not sexually active", and “Prefer not to answer”).
    1. Selected items include additional response options such as "Not applicable", "Not sexually active", and "Prefer not to answer". Users will need to apply a customized value to each of these (e.g., -99 = "Not applicable", 999 = "Not sexually active", and 9999 = "Prefer not to answer"). For example,
      1. QSTESTCD=PT01036A assessing symptom severity is rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”. The response "Not applicable" is also given and could be provided a value of -99.)
  6. The CRF represents up to 5 "other symptoms" to be recorded. In discussions with NIH, it was agreed to provide up to 10 "other symptoms" to be recorded if they existed. QSTESTCDs (QSTESTCDs "PT01082A" through "PT01091A") and severity of the symptom at its worst (QSTESTCDs "PT01082B" through "PT01091B").
  7. PRO-CTCAE V1.0 total scoring instructions have not yet been developed. Item-level scores are not combined (i.e., no total score nor symptom-specific scores are calculated).
  8. The time period of evaluation for the PRO-CTCAE V1.0 is populated in the QSEVLINT field in ISO 8601 format when the evaluation interval can be precisely described as duration. The evaluation interval for the PRO-CTCAE V1.0 is the past 7 days (QSEVLINT = "-P7D"). Please see the PRO-CTCAE website for more details on the evaluation interval.
  9. Items are divided into 15 subcategories represented in the QSSCAT variable. These categorizations represent how the symptom terms are categorized in the PRO-CTCAE V1.0 Item Library (Version 1.0). See Section 4, SDTM Mapping StrategyItems are divided into 14 subcategories represented in the QSSCAT variable. These categorizations represent how the symptom terms are categorized in the PRO-CTCAE V1.0 Item Library (Version 1.0). See Section 4, SDTM Mapping Strategy, for a list of these subcategory values. 
    1. The symptomatic AE being measured by a given item (e.g., the Symptom Term represented on the CRF corresponding to a given item) is stored in the SUPPQS dataset with the QNAM = "QSSYMPTM". This matches the symptom term identified in the PRO-CTCAE V1.0 Quick guide to the Item Library (Version 1.0).. The exception to this is the solicited verbatim symptom terms QSTESTCD = "PT01081 to PT01091B"with QNAM = "OTHER SYMPTOMS".
  10. Conditional Electronic conditional branching is recommended by NCI/NIH in the conduct of the electronic version of the PRO-CTCAE V1.0 for symptom terms that have two 2 or more items. The logic branches from frequency, then to severity, then to interference. For example, if frequency is > (greater than) never, you next pose the severity question, and if severity>noneseverity > none, you pose the interference question. Please reference  Please see the PRO-CTCAE website for more details on the electronic conditional branching approach. .
    1. When a paper version is administered, conditional branching does not apply.
  11. Some items on the PRO-CTCAE may be not done due to conditional branching per the electronic instrument instructions as described in assumption 7. A record is created with the assigned responses based on In the conduct of the PRO-CTCAE V1.0 it expects responses for each item and there should be no missing responses. Electronic branched severity items are assigned responses of 0 = "None" and electronic branched interference items are assigned 0 = "Not al all".
  12. The language in which the PRO-CTCAE V1.0 was administered (e.g., English, Spanish, Japanese) is collected with the Form Builder application and may be represented as a supplemental qualifier with QNAM = "QSLANGDC". Reference the PRO-CTCAE V1.0 website for a list of available language translations.
  13. Terminology
    1. QSCAT, QSTESTCD, and QSTEST values are included in CDISC Controlled Terminology.

    2. A full list of value sets for the qualifier, and result fields is provided in Section 4, SDTM Mapping Strategy.

3.2 Example for the PRO-CTCAE V1.0 QS Domain Model

  1. website FAQ and a QS supplemental qualifier variable is used to indicate an item was conditionally branched. Per NIH, these items are assigned values as follows: severity items are assigned responses of "None" and 0; interference items are assigned "Not at all" and 0. When an item is not done due to conditional branching, it is represented as follows:
    1. QNAM = “QSCBRFL”, QLABEL = “Conditionally Branched Item Flag “, QVAL = “Y” (this is a QS supplemental qualifier variable) 

    2. QSORRES

      1. For severity items, QSORRES = "None"

      2. For interference items, QSORRES = "Not at all"
    3. QSSTRESC = 0 and QSSTRESN = 0
  2. Records are created in qs.xpt for every item on the sponsor's version of the instrument. In the conduct of the PRO-CTCAE V1.0 NIH expects responses for each item and there should be no missing responses. 
    1. For items not done due to conditional branching, refer to assumption 8.
    2. In the unexpected situation where the reason is unknown, then QSORRES, QSSTRESC, and QSSTRESN are all missing; QSSTAT = "NOT DONE"; and QSREASND is missing.
  3. The language in which the PRO-CTCAE V1.0 was administered (e.g., English, Spanish, Japanese) is collected with the Form Builder application and may be represented as a supplemental qualifier with QNAM = "QSLANGDC". See the PRO-CTCAE V1.0 website for a list of available language translations.
  4. Terminology
    1. QSCAT, QSTESTCD, and QSTEST values are included in CDISC Controlled Terminology.

    2. A full list of value sets for the qualifier, and result fields is provided in Section 4, SDTM Mapping Strategy.

3.2 Example for the PRO-CTCAE V1.0 QS Domain Model

The PRO-CTCAE V1.0 example below shows the terminology used to implement the measurement system in the QS domain. This example shows the data for 1 subject collected at the baseline visit for a PRO-CTCAE V1.0. The example uses CDISC Controlled Terminology for QSTESTCD, QSTEST, and QSCAT. All original results, matching the CRF item response text, are represented in QSORRES.The PRO-CTCAE V1.0 example below shows the terminology used to implement the instrument in the QS domain. This example shows the data for 1 subject collected at the baseline visit for a PRO-CTCAE V1.0 instrument. The example uses CDISC Controlled Terminology for QSTESTCD, QSTEST, and QSCAT. All original results, matching the CRF item response text, are represented in QSORRES.This result is then represented as a standard numeric score in QSSTRESN and as a standard character representation in QSSTRESC.

Info

We are unable to make the example consistently show blue in the Wiki. All examples are updated for each QRS instrument so we ask that you please review the example below.

...

please review the example below.

Example 1: PRO-CTCAE V1.0 measuring the full set of symptoms
The table represents the items from the PRO-CTCAE V1.0 measurement system.

Dataset wrap
Nameqs
Rowcaps
Rows 20-21:

Represent the electronic conditional branching on data entry for the symptom hiccups did not occur and then the symptom of hiccups severity was assigned 0 = “None”.

Rows 24-26:Represent the electronic conditional branching on data entry for the symptom abdominal pain frequency did not occur. The symptom of abdominal pain severity is assigned 0 = “None” and abdominal pain interference is assigned 0 = “Not at all” for the standardized result values.
Rows 126-129:Represent two additional symptoms that existed for the subject.
Rows 130-145:Represent the symptoms "Other Symptom 3 and Other Symptom 3 Severity" through "Other Symptom 10 and Other Symptom 10 Severity" that did not exist for the subject. These symptoms are represented as "NOT DONE".
Dataset2
RowSTUDYIDDOMAINUSUBJIDQSSEQQSTESTCDQSTESTQSCATQSSCATQSORRESQSSTRESCQSSTRESNQSSTATQSREASNDQSLOBXFLVISITNUMQSDTCQSEVLINT
1STUDYXQS23-P00011PT01001APT01-Dry Mouth SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
2STUDYXQS23-P00012PT01002APT01-Difficulty Swallowing SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
3STUDYXQS23-P00013PT01003APT01-Mouth/Throat Sores SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
4STUDYXQS23-P00014PT01003BPT01-Mouth/Throat Sores InterferencePRO-CTCAE V1.0ORALA little bit11

Y12015-05-15-P7D
5STUDYXQS23-P00015PT01004APT01-Cracking Corners of Mouth SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
6STUDYXQS23-P00016PT01005APT01-Voice Quality Changes PresencePRO-CTCAE V1.0ORALNo00

Y12015-05-15-P7D
7STUDYXQS23-P00017PT01006APT01-Hoarseness SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
8STUDYXQS23-P00018PT01007APT01-Taste Changes SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
9STUDYXQS23-P00019PT01008APT01-Decreased Appetite SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
10STUDYXQS23-P000110PT01008BPT01-Decreased Appetite InterferencePRO-CTCAE V1.0GASTROINTESTINALSomewhat22

Y12015-05-15-P7D
11STUDYXQS23-P000111PT01009APT01-Nausea FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
12STUDYXQS23-P000112PT01009BPT01-Nausea SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
13STUDYXQS23-P000113PT01010APT01-Vomiting FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
14STUDYXQS23-P000114PT01010BPT01-Vomiting SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
15STUDYXQS23-P000115PT01011APT01-Heartburn FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
16STUDYXQS23-P000116PT01011BPT01-Heartburn SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
17STUDYXQS23-P000117PT01012APT01-Gas PresencePRO-CTCAE V1.0GASTROINTESTINALNo00

Y12015-05-15-P7D
18STUDYXQS23-P000118PT01013APT01-Bloating FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
19STUDYXQS23-P000119PT01013BPT01-Bloating SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
20STUDYXQS23-P000120PT01014APT01-Hiccups FrequencyPRO-CTCAE V1.0GASTROINTESTINALNever00

Y12015-05-15-P7D
21STUDYXQS23-P000121PT01014BPT01-Hiccups SeverityPRO-CTCAE V1.0GASTROINTESTINALNone00

Y12015-05-15-P7D
22STUDYXQS23-P000122PT01015APT01-Constipation SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
23STUDYXQS23-P000123PT01016APT01-Diarrhea FrequencyPRO-CTCAE V1.0GASTROINTESTINALRarely11

Y12015-05-15-P7D
24STUDYXQS23-P000124PT01017APT01-Abdominal Pain FrequencyPRO-CTCAE V1.0GASTROINTESTINALNever00

Y12015-05-15-P7D
25STUDYXQS23-P000125PT01017BPT01-Abdominal Pain SeverityPRO-CTCAE V1.0GASTROINTESTINALNone00

Y12015-05-15-P7D
26STUDYXQS23-P000126PT01017CPT01-Abdominal Pain InterferencePRO-CTCAE V1.0GASTROINTESTINALNot at all00

Y12015-05-15-P7D
27STUDYXQS23-P000127PT01018APT01-Fecal Incontinence FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
28STUDYXQS23-P000128PT01018BPT01-Fecal Incontinence InterferencePRO-CTCAE V1.0GASTROINTESTINALSomewhat22

Y12015-05-15-P7D
29STUDYXQS23-P000129PT01019APT01-Shortness of Breath SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
30STUDYXQS23-P000130PT01019BPT01-Shortness of Breath InterferencePRO-CTCAE V1.0RESPIRATORYSomewhat22

Y12015-05-15-P7D
31STUDYXQS23-P000131PT01020APT01-Cough SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
32STUDYXQS23-P000132PT01020BPT01-Cough InterferencePRO-CTCAE V1.0RESPIRATORYSomewhat22

Y12015-05-15-P7D
33STUDYXQS23-P000133PT01021APT01-Wheezing SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
34STUDYXQS23-P000134PT01022APT01-Swelling FrequencyPRO-CTCAE V1.0CARDIO/CIRCULATORYOccasionally22

Y12015-05-15-P7D
35STUDYXQS23-P000135PT01022BPT01-Swelling SeverityPRO-CTCAE V1.0CARDIO/CIRCULATORYMild11

Y12015-05-15-P7D
36STUDYXQS23-P000136PT01022CPT01-Swelling InterferencePRO-CTCAE V1.0CARDIO/CIRCULATORYSomewhat22

Y12015-05-15-P7D
37STUDYXQS23-P000137PT01023APT01-Heart Palpitations FrequencyPRO-CTCAE V1.0CARDIO/CIRCULATORYOccasionally22

Y12015-05-15-P7D
38STUDYXQS23-P000138PT01023BPT01-Heart Palpitations SeverityPRO-CTCAE V1.0CARDIO/CIRCULATORYMild11

Y12015-05-15-P7D
39STUDYXQS23-P000139PT01024APT01-Rash PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
40STUDYXQS23-P000140PT01025APT01-Skin Dryness SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
41STUDYXQS23-P000141PT01026APT01-Acne SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
42STUDYXQS23-P000142PT01027APT01-Hair Loss AmountPRO-CTCAE V1.0CUTANEOUSQuite a bit33

Y12015-05-15-P7D
43STUDYXQS23-P000143PT01028APT01-Itching SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
44STUDYXQS23-P000144PT01029APT01-Hives PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
45STUDYXQS23-P000145PT01030APT01-Hand-Foot Syndrome SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
46STUDYXQS23-P000146PT01031APT01-Nail Loss PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
47STUDYXQS23-P000147PT01032APT01-Nail Ridging PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
48STUDYXQS23-P000148PT01033APT01-Nail Discoloration PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
49STUDYXQS23-P000149PT01034APT01-Sensitivity to Sunlight PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
50STUDYXQS23-P000150PT01035APT01-Bed/Pressure Sores PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
51STUDYXQS23-P000151PT01036APT01-Radiation Skin Reaction SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
52STUDYXQS23-P000152PT01037APT01-Skin Darkening PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
53STUDYXQS23-P000153PT01038APT01-Stretch Marks PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
54STUDYXQS23-P000154PT01039APT01-Numbness & Tingling SeverityPRO-CTCAE V1.0NEUROLOGICALMild11

Y12015-05-15-P7D
55STUDYXQS23-P000155PT01039BPT01-Numbness & Tingling InterferencePRO-CTCAE V1.0NEUROLOGICALSomewhat22

Y12015-05-15-P7D
56STUDYXQS23-P000156PT01040APT01-Dizziness SeverityPRO-CTCAE V1.0NEUROLOGICALMild11

Y12015-05-15-P7D
57STUDYXQS23-P000157PT01040BPT01-Dizziness InterferencePRO-CTCAE V1.0NEUROLOGICALSomewhat22

Y12015-05-15-P7D
58STUDYXQS23-P000158PT01041APT01-Blurred Vision SeverityPRO-CTCAE V1.0VISUAL/PERCEPTUALMild11

Y12015-05-15-P7D
59STUDYXQS23-P000159PT01041BPT01-Blurred Vision InterferencePRO-CTCAE V1.0VISUAL/PERCEPTUALSomewhat22

Y12015-05-15-P7D
60STUDYXQS23-P000160PT01042APT01-Flashing Lights in Eyes PresencePRO-CTCAE V1.0VISUAL/PERCEPTUALNo00

Y12015-05-15-P7D
61STUDYXQS23-P000161PT01043APT01-Visual Floaters PresencePRO-CTCAE V1.0VISUAL/PERCEPTUALNo00

Y12015-05-15-P7D
62STUDYXQS23-P000162PT01044APT01-Watery Eyes SeverityPRO-CTCAE V1.0VISUAL/PERCEPTUALMild11

Y12015-05-15-P7D
63STUDYXQS23-P000163PT01044BPT01-Watery Eyes InterferencePRO-CTCAE V1.0VISUAL/PERCEPTUALSomewhat22

Y12015-05-15-P7D
64STUDYXQS23-P000164PT01045APT01-Ringing in Ears SeverityPRO-CTCAE V1.0VISUAL/PERCEPTUALMild11

Y12015-05-15-P7D
65
Dataset wrap
Nameqs
1
Rowcaps
Rows 126-129:Represent two additional symptoms that existed for the subject.
Rows 130-145:Represent the symptoms "Other Symptom 3 and Other Symptom 3 Severity" through "Other Symptom 10 and Other Symptom 10 Severity" that did not exist for the subject.
Dataset2
RowSTUDYIDDOMAINUSUBJIDQSSEQQSTESTCDQSTESTQSCATQSSCATQSORRESQSSTRESCQSSTRESNQSLOBXFLVISITNUMQSDTCQSEVLINT
STUDYXQS23-P0001
1
65
PT01001A
PT01046APT01-
Dry Mouth
Concentration Problems SeverityPRO-CTCAE V1.0
ORAL
ATTENTION/MEMORYMild11

Y12015-05-15-P7D
2
66STUDYXQS23-P0001
2
66
PT01002A
PT01046BPT01-
Difficulty Swallowing Severity
Concentration Problems InterferencePRO-CTCAE V1.0
ORAL
ATTENTION/MEMORY
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
3
67STUDYXQS23-P0001
3
67
PT01003A
PT01047APT01-
Mouth/Throat Sores
Memory Problems SeverityPRO-CTCAE V1.0
ORAL
ATTENTION/MEMORYMild11

Y12015-05-15-P7D
4
68STUDYXQS23-P0001
4
68
PT01003B
PT01047BPT01-
Mouth/Throat Sores
Memory Problems InterferencePRO-CTCAE V1.0
ORALA little bit1
ATTENTION/MEMORYSomewhat22
1


Y12015-05-15-P7D
5
69STUDYXQS23-P0001
5
69
PT01004A
PT01048APT01-
Cracking Corners of Mouth Severity
General Pain FrequencyPRO-CTCAE V1.0
ORAL
PAIN
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
6
70STUDYXQS23-P0001
6
70
PT01005A
PT01048BPT01-
Voice Quality Changes Presence
General Pain SeverityPRO-CTCAE V1.0PAIN
ORAL
Mild
No
1
0
1

Y12015-05-15-P7D
7
71STUDYXQS23-P0001
7
71
PT01006A
PT01048CPT01-
Hoarseness Severity
General Pain InterferencePRO-CTCAE V1.0
ORAL
PAIN
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
8
72STUDYXQS23-P0001
8
72
PT01007A
PT01049APT01-
Taste Changes Severity
Headache FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
9
73STUDYXQS23-P0001
9
73
PT01008A
PT01049BPT01-
Decreased Appetite
Headache SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
PAINMild11

Y12015-05-15-P7D
10
74STUDYXQS23-P0001
10
74
PT01008B
PT01049CPT01-
Decreased Appetite
Headache InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
PAINSomewhat22

Y12015-05-15-P7D
11
75STUDYXQS23-P0001
11
75
PT01009A
PT01050APT01-
Nausea
Muscle Pain FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
PAINOccasionally22

Y12015-05-15-P7D
12
76STUDYXQS23-P0001
12
76
PT01009B
PT01050BPT01-
Nausea
Muscle Pain SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
PAINMild11

Y12015-05-15-P7D
13
77STUDYXQS23-P0001
13
77
PT01010A
PT01050CPT01-
Vomiting Frequency
Muscle Pain InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Occasionally
Somewhat22

Y12015-05-15-P7D
14
78STUDYXQS23-P0001
14
78
PT01010B
PT01051APT01-
Vomiting Severity
Joint Pain FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
15
79STUDYXQS23-P0001
15
79
PT01011A
PT01051BPT01-
Heartburn Frequency
Joint Pain SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Occasionally
Mild
2
1
2
1

Y12015-05-15-P7D
16
80STUDYXQS23-P0001
16
80
PT01011B
PT01051CPT01-
Heartburn Severity
Joint Pain InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
17
81STUDYXQS23-P0001
17
81
PT01012A
PT01052APT01-
Gas Presence
Insomnia SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
SLEEP/WAKE
No
Mild
0
1
0
1

Y12015-05-15-P7D
18
82STUDYXQS23-P0001
18
82
PT01013A
PT01052BPT01-
Bloating Frequency
Insomnia InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
SLEEP/WAKE
Occasionally
Somewhat22

Y12015-05-15-P7D
19
83STUDYXQS23-P0001
19
83
PT01013B
PT01053APT01-
Bloating
Fatigue SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
SLEEP/WAKEMild11

Y12015-05-15-P7D
20
84STUDYXQS23-P0001
20
84
PT01014A
PT01053BPT01-
Hiccups Frequency
Fatigue InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
SLEEP/WAKE
Never
Somewhat
0
2
0
2

Y12015-05-15-P7D
21
85STUDYXQS23-P0001
21
85
PT01014B
PT01054APT01-
Hiccups Severity
Anxious FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
None
Occasionally
0
2
0
2

Y12015-05-15-P7D
22
86STUDYXQS23-P0001
22
86
PT01015A
PT01054BPT01-
Constipation
Anxious SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
MOODMild11

Y12015-05-15-P7D
23
87STUDYXQS23-P0001
23
87
PT01016A
PT01054CPT01-
Diarrhea Frequency
Anxious InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
Rarely
Somewhat
1
2
1
2

Y12015-05-15-P7D
24
88STUDYXQS23-P0001
24
88
PT01017A
PT01055APT01-
Abdominal Pain
Discouraged FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
Never
Occasionally
0
2
0
2

Y12015-05-15-P7D
25
89STUDYXQS23-P0001
25
89
PT01017B
PT01055BPT01-
Abdominal Pain
Discouraged SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
None
Mild
0
1
0
1

Y12015-05-15-P7D
26
90STUDYXQS23-P0001
26
90
PT01017C
PT01055CPT01-
Abdominal Pain
Discouraged InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
Not at all
Somewhat
0
2
0
2

Y12015-05-15-P7D
27
91STUDYXQS23-P0001
27
91
PT01018A
PT01056APT01-
Fecal Incontinence
Sad FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
MOODOccasionally22

Y12015-05-15-P7D
28
92STUDYXQS23-P0001
28
92
PT01018B
PT01056BPT01-
Fecal Incontinence Interference
Sad SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
Somewhat
Mild
2
1
2
1

Y12015-05-15-P7D
29
93STUDYXQS23-P0001
29
93
PT01019A
PT01056CPT01-
Shortness of Breath Severity
Sad InterferencePRO-CTCAE V1.0
RESPIRATORY
MOOD
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
30
94STUDYXQS23-P0001
30
94
PT01019B
PT01057APT01-
Shortness of Breath Interference
Irregular Menstrual Period PresencePRO-CTCAE V1.0
RESPIRATORY
GYNECOLOGIC/URINARY
Somewhat
No
2
0
2
0

Y12015-05-15-P7D
31
95STUDYXQS23-P0001
31
95
PT01020A
PT01058APT01-
Cough Severity
Missed Menstrual Period PresencePRO-CTCAE V1.0
RESPIRATORY
GYNECOLOGIC/URINARY
Mild
No
1
0
1
0

Y12015-05-15-P7D
32
96STUDYXQS23-P0001
32
96
PT01020B
PT01059APT01-
Cough Interference
Vaginal Discharge AmountPRO-CTCAE V1.0
RESPIRATORY
GYNECOLOGIC/URINARYSomewhat22

Y12015-05-15-P7D
33
97STUDYXQS23-P0001
33
97
PT01021A
PT01060APT01-
Wheezing
Vaginal Dryness SeverityPRO-CTCAE V1.0
RESPIRATORY
GYNECOLOGIC/URINARYMild11

Y12015-05-15-P7D
34
98STUDYXQS23-P0001
34
98
PT01022A
PT01061APT01-
Swelling Frequency
Painful Urination SeverityPRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARY
Occasionally
Mild
2
1
2
1

Y12015-05-15-P7D
35
99STUDYXQS23-P0001
35
99
PT01022B
PT01062APT01-
Swelling Severity
Urinary Urgency FrequencyPRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARY
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
36
100STUDYXQS23-P0001
36
100
PT01022C
PT01062BPT01-
Swelling
Urinary Urgency InterferencePRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARYSomewhat22

Y12015-05-15-P7D
37
191STUDYXQS23-P0001
37
191
PT01023A
PT01063APT01-
Heart Palpitations
Urinary Frequency FrequencyPRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARYOccasionally22

Y12015-05-15-P7D
38
102STUDYXQS23-P0001
38
102
PT01023B
PT01063BPT01-
Heart Palpitations Severity
Urinary Frequency InterferencePRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARY
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
39
103STUDYXQS23-P0001
39
103
PT01024A
PT01064APT01-
Rash
Urine Color Change PresencePRO-CTCAE V1.0
CUTANEOUS
GYNECOLOGIC/URINARYNo00

Y12015-05-15-P7D
40
104STUDYXQS23-P0001
40
104
PT01025A
PT01065APT01-
Skin Dryness Severity
Urinary Incontinence FrequencyPRO-CTCAE V1.0
CUTANEOUS
GYNECOLOGIC/URINARY
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
41
105STUDYXQS23-P0001
41
105
PT01026A
PT01065BPT01-
Acne Severity
Urinary Incontinence InterferencePRO-CTCAE V1.0
CUTANEOUS
GYNECOLOGIC/URINARY
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
42
106STUDYXQS23-P0001
42
106
PT01027A
PT01066APT01-
Hair Loss Amount
Achieve&Maintain Erection SeverityPRO-CTCAE V1.0
CUTANEOUS
SEXUAL
Quite a bit
Mild
3
1
3
1

Y12015-05-15-P7D
43
107STUDYXQS23-P0001
43
107
PT01028A
PT01067APT01-
Itching Severity
Ejaculation FrequencyPRO-CTCAE V1.0
CUTANEOUS
SEXUAL
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
44
108STUDYXQS23-P0001
44
108
PT01029A
PT01068APT01-
Hives Presence
Decreased Libido SeverityPRO-CTCAE V1.0
CUTANEOUS
SEXUAL
No
Mild
0
1
0
1

Y12015-05-15-P7D
45
109STUDYXQS23-P0001
45
109
PT01030A
PT01069APT01-
Hand-Foot Syndrome Severity
Delayed Orgasm PresencePRO-CTCAE V1.0
CUTANEOUS
SEXUAL
Mild
No
1
0
1
0

Y12015-05-15-P7D
46
110STUDYXQS23-P0001
46
110
PT01031A
PT01070APT01-
Nail Loss
Unable to Have Orgasm PresencePRO-CTCAE V1.0
CUTANEOUS
SEXUALNo00

Y12015-05-15-P7D
47
111STUDYXQS23-P0001
47
111
PT01032A
PT01071APT01-
Nail Ridging Presence
Pain w/Sexual Intercourse SeverityPRO-CTCAE V1.0
CUTANEOUS
SEXUAL
No
Mild
0
1
0
1

Y12015-05-15-P7D
48
112STUDYXQS23-P0001
48
112
PT01033A
PT01072APT01-
Nail Discoloration Presence
Breast Swelling&Tenderness SeverityPRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUS
No
Mild
0
1
0
1

Y12015-05-15-P7D
49
113STUDYXQS23-P0001
49
113
PT01034A
PT01073APT01-
Sensitivity to Sunlight
Bruising PresencePRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUSNo00

Y12015-05-15-P7D
50
114STUDYXQS23-P0001
50
114
PT01035A
PT01074APT01-
Bed/Pressure Sores Presence
Chills FrequencyPRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUS
No
Occasionally
0
2
0
2

Y12015-05-15-P7D
51
115STUDYXQS23-P0001
51
115
PT01036A
PT01074BPT01-
Radiation Skin Reaction
Chills SeverityPRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUSMild11

Y12015-05-15-P7D
52
116STUDYXQS23-P0001
52
116
PT01037A
PT01075APT01-
Skin Darkening Presence
Increased Sweating FrequencyPRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUS
No
Occasionally
0
2
0
2

Y12015-05-15-P7D
53
117STUDYXQS23-P0001
53
117
PT01038A
PT01075BPT01-
Stretch Marks Presence
Increased Sweating SeverityPRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUS
No
Mild
0
1
0
1

Y12015-05-15-P7D
54
118STUDYXQS23-P0001
54
118
PT01039A
PT01076APT01-
Numbness & Tingling Severity
Decreased Sweating PresencePRO-CTCAE V1.0
NEUROLOGICAL
MISCELLANEOUS
Mild
No
1
0
1
0

Y12015-05-15-P7D
55
118STUDYXQS23-P0001
55
118
PT01039B
PT01077APT01-
Numbness & Tingling Interference
Hot Flashes FrequencyPRO-CTCAE V1.0
NEUROLOGICAL
MISCELLANEOUS
Somewhat
Occasionally22

Y12015-05-15-P7D
56
120STUDYXQS23-P0001
56
120
PT01040A
PT01077BPT01-
Dizziness
Hot Flashes SeverityPRO-CTCAE V1.0
NEUROLOGICAL
MISCELLANEOUSMild11

Y12015-05-15-P7D
57
121STUDYXQS23-P0001
57
121
PT01040B
PT01078APT01-
Dizziness Interference
Nosebleed FrequencyPRO-CTCAE V1.0
NEUROLOGICAL
MISCELLANEOUS
Somewhat
Occasionally22

Y12015-05-15-P7D
58
122STUDYXQS23-P0001
58
122
PT01041A
PT01078BPT01-
Blurred Vision
Nosebleed SeverityPRO-CTCAE V1.0
VISUAL/PERCEPTUAL
MISCELLANEOUSMild11

Y12015-05-15-P7D
59
123STUDYXQS23-P0001
59
123
PT01041B
PT01079APT01-
Blurred Vision Interference
Pain&Swelling at Inj Site PresencePRO-CTCAE V1.0
VISUAL/PERCEPTUAL
MISCELLANEOUS
Somewhat
No
2
0
2
0

Y12015-05-15-P7D
60
124STUDYXQS23-P0001
60
124
PT01042A
PT01080APT01-
Flashing Lights in Eyes Presence
Body Odor SeverityPRO-CTCAE V1.0
VISUAL/PERCEPTUAL
MISCELLANEOUS
No
Mild
0
1
0
1

Y12015-05-15-P7D
61
125STUDYXQS23-P0001
61
125
PT01043A
PT01081PT01-
Visual Floaters Presence
Any Other Symptoms ReportedPRO-CTCAE V1.0
VISUAL/PERCEPTUALNo0
OTHER SYMPTOMSYes11
0


Y12015-05-15-P7D
62
126STUDYXQS23-P0001
62
126
PT01044A
PT01082APT01-
Watery Eyes Severity
Other Symptom 1PRO-CTCAE V1.0
VISUAL/PERCEPTUALMild
OTHER SYMPTOMSAnother symptom 1Another symptom 1


Y12015-05-15-P7D
63
127STUDYXQS23-P0001
63
127
PT01044B
PT01082BPT01-
Watery Eyes Interference
Other Symptom 1 SeverityPRO-CTCAE V1.0
VISUAL/PERCEPTUALSomewhat2
OTHER SYMPTOMSMild11
2


Y12015-05-15-P7D
64
128STUDYXQS23-P0001
64
128
PT01045A
PT01083APT01-
Ringing in Ears Severity
Other Symptom 2PRO-CTCAE V1.0
VISUAL/PERCEPTUALMild1
OTHER SYMPTOMSAnother symptom 2Another symptom 2
1



Y12015-05-15-P7D
65
129STUDYXQS23-P0001
65
129
PT01046A
PT01083BPT01-
Concentration Problems
Other Symptom 2 SeverityPRO-CTCAE V1.0
ATTENTION/MEMORY
OTHER SYMPTOMSMild11

Y12015-05-15-P7D
66
130STUDYXQS23-P0001
66
130
PT01046B
PT01084APT01-
Concentration Problems Interference
Other Symptom 3PRO-CTCAE V1.0
ATTENTION/MEMORYSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
67
131STUDYXQS23-P0001
67
131
PT01047A
PT01084BPT01-
Memory Problems
Other Symptom 3 SeverityPRO-CTCAE V1
.0ATTENTION/MEMORYMild1
.0OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
68
132STUDYXQS23-P0001
68
132
PT01047B
PT01085APT01-
Memory Problems Interference
Other Symptom 4PRO-CTCAE V1.0
ATTENTION/MEMORYSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
69
133STUDYXQS23-P0001
69
133
PT01048A
PT01085BPT01-
General Pain Frequency
Other Symptom 4 SeverityPRO-CTCAE V1.0
PAINOccasionally2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
70
134STUDYXQS23-P0001
70
134
PT01048B
PT01086APT01-
General Pain Severity
Other Symptom 5PRO-CTCAE V1.0
PAINMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
71
135STUDYXQS23-P0001
71
135
PT01048C
PT01086BPT01-
General Pain Interference
Other Symptom 5 SeverityPRO-CTCAE V1.0
PAINSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
72
136STUDYXQS23-P0001
72
136
PT01049A
PT01087APT01-
Headache Frequency
Other Symptom 6PRO-CTCAE V1.0
PAINOccasionally2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
73
137STUDYXQS23-P0001
73
137
PT01049B
PT01087BPT01-
Headache
Other Symptom 6 SeverityPRO-CTCAE V1.0
PAINMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
74
138STUDYXQS23-P0001
74
138
PT01049C
PT01088APT01-
Headache Interference
Other Symptom 7PRO-CTCAE V1.0
PAINSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
75
139STUDYXQS23-P0001
75
139
PT01050A
PT01088BPT01-
Muscle Pain Frequency
Other Symptom 7 SeverityPRO-CTCAE V1.0
PAINOccasionally2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
76
140STUDYXQS23-P0001
76
140
PT01050B
PT01089APT01-
Muscle Pain Severity
Other Symptom 8PRO-CTCAE V1.0
PAINMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
77
141STUDYXQS23-P0001
77
141
PT01050C
PT01089BPT01-
Muscle Pain Interference
Other Symptom 8 SeverityPRO-CTCAE V1.0
PAINSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
78
142STUDYXQS23-P0001
78
142
PT01051A
PT01090APT01-
Joint Pain Frequency
Other Symptom 9PRO-CTCAE V1.0
PAINOccasionally2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
79
143STUDYXQS23-P0001
79
143
PT01051B
PT01090BPT01-
Joint Pain
Other Symptom 9 SeverityPRO-CTCAE V1.0
PAINMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
80
144STUDYXQS23-P0001
80
144
PT01051C
PT01091APT01-
Joint Pain Interference
Other Symptom 10PRO-CTCAE V1.0
PAINSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
81
145STUDYXQS23-P0001
81
145
PT01052A
PT01091BPT01-
Insomnia
Other Symptom 10 SeverityPRO-CTCAE V1.0
SLEEP/WAKEMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
82STUDYXQS23-P000182PT01052BPT01-Insomnia InterferencePRO-CTCAE V1.0SLEEP/WAKESomewhat22Y12015-05-15-P7D83


The SUPPQS dataset shows the items in the QS dataset which have assigned responses (QSCBRFL = "Y") due to electronic conditional branching and also relates the symptom terms from the annotated Item Library v1.0 form to each symptom item represented in the QS dataset.

85
Dataset wrap
Namesuppqs
Dataset2
tableidsuppqs
STUDYIDRDOMAINUSUBJIDIDVARIDVARVALQNAMQLABELQVALQORIG
STUDYXQS23-P0001
83
QSSEQ
PT01053APT01-Fatigue SeverityPRO-CTCAE V1.0SLEEP/WAKEMild11Y12015-05-15-P7D
21QSCBRFLConditionally Branched Item FlagYASSIGNED
84
STUDYXQS23-P0001QSSEQ25
84PT01053BPT01-Fatigue InterferencePRO-CTCAE V1.0SLEEP/WAKESomewhat22Y12015-05-15-P7D
QSCBRFLConditionally Branched Item FlagYASSIGNED
STUDYXQS23-P0001QSSEQ26QSCBRFLConditionally Branched Item FlagYASSIGNED
STUDYXQS23-P0001QSTESTCDPT01001A
85
QSSYMPTM
PT01054APT01-Anxious FrequencyPRO-CTCAE V1.0MOODOccasionally22Y12015-05-15-P7D86
Symptom TermDRY MOUTHCRF
STUDYXQS23-P0001QSTESTCDPT01002AQSSYMPTMSymptom TermDIFFICULTY SWALLOWINGCRF
STUDYXQS23-P0001QSTESTCDPT01003A
86
QSSYMPTM
PT01054BPT01-Anxious SeverityPRO-CTCAE V1.0MOODMild11Y12015-05-15-P7D87
Symptom TermMOUTH/THROAT SORESCRF
STUDYXQS23-P0001QSTESTCDPT01003BQSSYMPTMSymptom TermMOUTH/THROAT SORESCRF
STUDYXQS23-P0001QSTESTCDPT01004A
87
QSSYMPTM
PT01054CPT01-Anxious InterferencePRO-CTCAE V1.0MOODSomewhat22Y12015-05-15-P7D88
Symptom TermCRACKING AT THE CORNERS OF THE MOUTH (CHEILOSIS/CHEILITIS)CRF
STUDYXQS23-P0001QSTESTCDPT01005AQSSYMPTMSymptom TermVOICE QUALITY CHANGESCRF
STUDYXQS23-P0001QSTESTCDPT01006A
88
QSSYMPTM
PT01055APT01-Discouraged FrequencyPRO-CTCAE V1.0MOODOccasionally22Y12015-05-15-P7D89
Symptom TermHOARSENESSCRF
STUDYXQS23-P0001QSTESTCDPT01007AQSSYMPTMSymptom TermTASTE CHANGESCRF
STUDYXQS23-P0001QSTESTCDPT01008A
89
QSSYMPTM
PT01055BPT01-Discouraged SeverityPRO-CTCAE V1.0MOODMild11Y12015-05-15-P7D90
Symptom TermDECREASED APPETITECRF
STUDYXQS23-P0001QSTESTCDPT01008BQSSYMPTMSymptom TermDECREASED APPETITECRF
STUDYXQS23-P0001QSTESTCDPT01009A
90
QSSYMPTM
PT01055CPT01-Discouraged InterferencePRO-CTCAE V1.0MOODSomewhat22Y12015-05-15-P7D91
Symptom TermNAUSEACRF
STUDYXQS23-P0001QSTESTCDPT01009BQSSYMPTMSymptom TermNAUSEACRF
STUDYXQS23-P0001QSTESTCDPT01010A
91
QSSYMPTM
PT01056APT01-Sad FrequencyPRO-CTCAE V1.0MOODOccasionally22Y12015-05-15-P7D92
Symptom TermVOMITINGCRF
STUDYXQS23-P0001QSTESTCDPT01010BQSSYMPTMSymptom TermVOMITINGCRF
STUDYXQS23-P0001
92
QSTESTCD
PT01056BPT01-Sad SeverityPRO-CTCAE V1.0MOODMild11Y12015-05-15-P7D93
PT01011AQSSYMPTMSymptom TermHEARTBURNCRF
STUDYXQS23-P0001QSTESTCDPT01011B
93
QSSYMPTM
PT01056CPT01-Sad InterferencePRO-CTCAE V1.0MOODSomewhat22Y12015-05-15-P7D94
Symptom TermHEARTBURNCRF
STUDYXQS23-P0001QSTESTCDPT01012AQSSYMPTMSymptom TermGASCRF
STUDYXQS23-P0001QSTESTCDPT01013A
94
QSSYMPTM
PT01057APT01-Irregular Menstrual Period PresencePRO-CTCAE V1.0GYNECOLOGIC/URINARYNo00Y12015-05-15-P7D95
Symptom TermBLOATINGCRF
STUDYXQS23-P0001QSTESTCDPT01013BQSSYMPTMSymptom TermBLOATINGCRF
STUDYXQS23-P0001
95
QSTESTCD
PT01058APT01-Missed Menstrual Period PresencePRO-CTCAE V1.0GYNECOLOGIC/URINARYNo00Y12015-05-15-P7D96
PT01014AQSSYMPTMSymptom TermHICCUPSCRF
STUDYXQS23-P0001QSTESTCDPT01014BQSSYMPTMSymptom TermHICCUPSCRF
STUDYXQS23-P0001
96PT01059APT01-Vaginal Discharge AmountPRO-CTCAE V1.0GYNECOLOGIC/URINARYSomewhat2Y12015-05-15-P7D97
QSTESTCDPT01015AQSSYMPTMSymptom TermCONSTIPATIONCRF
STUDYXQS23-P0001QSTESTCDPT01016AQSSYMPTMSymptom TermDIARRHEACRF
STUDYXQS23-P0001QSTESTCDPT01017A
97
QSSYMPTM
PT01060APT01-Vaginal Dryness SeverityPRO-CTCAE V1.0GYNECOLOGIC/URINARYMild11Y12015-05-15-P7D98
Symptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01017BQSSYMPTMSymptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01017C
98
QSSYMPTM
PT01061APT01-Painful Urination SeverityPRO-CTCAE V1.0GYNECOLOGIC/URINARYMild11Y12015-05-15-P7D99
Symptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01018AQSSYMPTMSymptom TermFECAL INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01018B
99
QSSYMPTM
PT01062APT01-Urinary Urgency FrequencyPRO-CTCAE V1.0GYNECOLOGIC/URINARYOccasionally22Y12015-05-15-P7D100
Symptom TermFECAL INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01019AQSSYMPTMSymptom TermSHORTNESS OF BREATHCRF
STUDYXQS23-P0001QSTESTCDPT01019B
100
QSSYMPTM
PT01062BPT01-Urinary Urgency InterferencePRO-CTCAE V1.0GYNECOLOGIC/URINARYSomewhat22Y12015-05-15-P7D191
Symptom TermSHORTNESS OF BREATHCRF
STUDYXQS23-P0001QSTESTCDPT01020AQSSYMPTMSymptom TermCOUGHCRF
STUDYXQS23-P0001QSTESTCDPT01020B
191
QSSYMPTM
PT01063APT01-Urinary Frequency FrequencyPRO-CTCAE V1.0GYNECOLOGIC/URINARYOccasionally22Y12015-05-15-P7D102
Symptom TermCOUGHCRF
STUDYXQS23-P0001QSTESTCDPT01021AQSSYMPTMSymptom TermWHEEZINGCRF
STUDYXQS23-P0001QSTESTCDPT01022A
102
QSSYMPTM
PT01063BPT01-Urinary Frequency InterferencePRO-CTCAE V1.0GYNECOLOGIC/URINARYSomewhat22Y12015-05-15-P7D103
Symptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022BQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022C
103
QSSYMPTM
PT01064APT01-Urine Color Change PresencePRO-CTCAE V1.0GYNECOLOGIC/URINARYNo00Y12015-05-15-P7D104
Symptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01023AQSSYMPTMSymptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01023B
104
QSSYMPTM
PT01065APT01-Urinary Incontinence FrequencyPRO-CTCAE V1.0GYNECOLOGIC/URINARYOccasionally22Y12015-05-15-P7D105
Symptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01024AQSSYMPTMSymptom TermRASHCRF
STUDYXQS23-P0001QSTESTCDPT01025A
105
QSSYMPTM
PT01065BPT01-Urinary Incontinence InterferencePRO-CTCAE V1.0GYNECOLOGIC/URINARYSomewhat22Y12015-05-15-P7D106
Symptom TermSKIN DRYNESSCRF
STUDYXQS23-P0001QSTESTCDPT01026AQSSYMPTMSymptom TermACNECRF
STUDYXQS23-P0001QSTESTCDPT01027A
106
QSSYMPTM
PT01066APT01-Achieve&Maintain Erection SeverityPRO-CTCAE V1.0SEXUALMild11Y12015-05-15-P7D107
Symptom TermHAIR LOSSCRF
STUDYXQS23-P0001QSTESTCDPT01028AQSSYMPTMSymptom TermITCHINGCRF
STUDYXQS23-P0001QSTESTCDPT01029A
107
QSSYMPTM
PT01067APT01-Ejaculation FrequencyPRO-CTCAE V1.0SEXUALOccasionally22Y12015-05-15-P7D108
Symptom TermHIVESCRF
STUDYXQS23-P0001QSTESTCDPT01030AQSSYMPTMSymptom TermHAND-FOOT SYNDROMECRF
STUDYXQS23-P0001QSTESTCDPT01031A
108
QSSYMPTM
PT01068APT01-Decreased Libido SeverityPRO-CTCAE V1.0SEXUALMild11Y12015-05-15-P7D109
Symptom TermNAIL LOSSCRF
STUDYXQS23-P0001QSTESTCDPT01032AQSSYMPTMSymptom TermNAIL RIDGINGCRF
STUDYXQS23-P0001QSTESTCDPT01033A
109
QSSYMPTM
PT01069APT01-Delayed Orgasm PresencePRO-CTCAE V1.0SEXUALNo00Y12015-05-15-P7D110
Symptom TermNAIL DISCOLORATIONCRF
STUDYXQS23-P0001QSTESTCDPT01034AQSSYMPTMSymptom TermSENSITIVITY TO SUNLIGHTCRF
STUDYXQS23-P0001QSTESTCD
110
PT01035A
PT01070APT01-Unable to Have Orgasm PresencePRO-CTCAE V1.0SEXUALNo00Y12015-05-15-P7D111
QSSYMPTMSymptom TermBED/PRESSURE SORESCRF
STUDYXQS23-P0001QSTESTCDPT01036AQSSYMPTMSymptom TermRADIATION SKIN REACTIONCRF
STUDYXQS23-P0001QSTESTCDPT01037A
111
QSSYMPTM
PT01071APT01-Pain w/Sexual Intercourse SeverityPRO-CTCAE V1.0SEXUALMild11Y12015-05-15-P7D112
Symptom TermSKIN DARKENINGCRF
STUDYXQS23-P0001QSTESTCDPT01038AQSSYMPTMSymptom TermSTRETCH MARKSCRF
STUDYXQS23-P0001QSTESTCDPT01039A
112
QSSYMPTM
PT01072APT01-Breast Swelling&Tenderness SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D113
Symptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001QSTESTCDPT01039BQSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001QSTESTCDPT01040A
113
QSSYMPTM
PT01073APT01-Bruising PresencePRO-CTCAE V1.0MISCELLANEOUSNo00Y12015-05-15-P7D114
Symptom TermDIZZINESSCRF
STUDYXQS23-P0001QSTESTCDPT01040BQSSYMPTMSymptom TermDIZZINESSCRF
STUDYXQS23-P0001QSTESTCDPT01041A
114
QSSYMPTM
PT01074APT01-Chills FrequencyPRO-CTCAE V1.0MISCELLANEOUSOccasionally22Y12015-05-15-P7D115
Symptom TermBLURRED VISIONCRF
STUDYXQS23-P0001QSTESTCDPT01041BQSSYMPTMSymptom TermBLURRED VISIONCRF
STUDYXQS23-P0001QSTESTCDPT01042A
115
QSSYMPTM
PT01074BPT01-Chills SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D116
Symptom TermFLASHING LIGHTSCRF
STUDYXQS23-P0001QSTESTCDPT01043AQSSYMPTMSymptom TermVISUAL FLOATERSCRF
STUDYXQS23-P0001QSTESTCDPT01044A
116
QSSYMPTM
PT01075APT01-Increased Sweating FrequencyPRO-CTCAE V1.0MISCELLANEOUSOccasionally22Y12015-05-15-P7D117
Symptom TermWATERY EYESCRF
STUDYXQS23-P0001QSTESTCDPT01044BQSSYMPTMSymptom TermWATERY EYESCRF
STUDYXQS23-P0001QSTESTCDPT01045A
117
QSSYMPTM
PT01075BPT01-Increased Sweating SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D118
Symptom TermRINGING IN EARSCRF
STUDYXQS23-P0001QSTESTCDPT01046AQSSYMPTMSymptom TermCONCENTRATIONCRF
STUDYXQS23-P0001QSTESTCDPT01046B
118
QSSYMPTM
PT01076APT01-Decreased Sweating PresencePRO-CTCAE V1.0MISCELLANEOUSNo00Y12015-05-15-P7D
Symptom TermCONCENTRATIONCRF
STUDYXQS23-P0001QSTESTCDPT01047AQSSYMPTMSymptom TermMEMORYCRF
118
STUDYXQS23-P0001QSTESTCDPT01047B
118
QSSYMPTM
PT01077APT01-Hot Flashes FrequencyPRO-CTCAE V1.0MISCELLANEOUSOccasionally22Y12015-05-15-P7D120
Symptom TermMEMORYCRF
STUDYXQS23-P0001QSTESTCDPT01048AQSSYMPTMSymptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01048B
120
QSSYMPTM
PT01077BPT01-Hot Flashes SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D121
Symptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01048CQSSYMPTMSymptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01049A
121
QSSYMPTM
PT01078APT01-Nosebleed FrequencyPRO-CTCAE V1.0MISCELLANEOUSOccasionally22Y12015-05-15-P7D122
Symptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01049BQSSYMPTMSymptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01049C
122
QSSYMPTM
PT01078BPT01-Nosebleed SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D123
Symptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01050AQSSYMPTMSymptom TermMUSCLE PAINCRF
STUDYXQS23-P0001
123PT01079APT01-Pain&Swelling at Inj Site PresencePRO-CTCAE V1.0MISCELLANEOUSNo00Y12015-05-15-P7D124
QSTESTCDPT01050BQSSYMPTMSymptom TermMUSCLE PAINCRF
STUDYXQS23-P0001QSTESTCDPT01050CQSSYMPTMSymptom TermMUSCLE PAINCRF
STUDYXQS23-P0001QSTESTCDPT01051A
124
QSSYMPTM
PT01080APT01-Body Odor SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D125
Symptom TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCDPT01051BQSSYMPTMSymptom TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCDPT01051C
125
QSSYMPTM
PT01081PT01-Any Other Symptoms ReportedPRO-CTCAE V1.0OTHER SYMPTOMSYes11Y12015-05-15-P7D126
Symptom TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCDPT01052AQSSYMPTMSymptom TermINSOMNIACRF
STUDYXQS23-P0001QSTESTCD
126
PT01052B
PT01082A
QSSYMPTM
PT01-Other Symptom 1PRO-CTCAE V1.0OTHER SYMPTOMSAnother symptom 1Another symptom 1Y12015-05-15-P7D127
Symptom TermINSOMNIACRF
STUDYXQS23-P0001QSTESTCDPT01053AQSSYMPTMSymptom TermFATIGUECRF
STUDYXQS23-P0001QSTESTCD
127
PT01053B
PT01082B
QSSYMPTM
PT01-Other Symptom 1 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSMild11Y12015-05-15-P7D128
Symptom TermFATIGUECRF
STUDYXQS23-P0001QSTESTCDPT01054AQSSYMPTMSymptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCD
128
PT01054B
PT01083A
QSSYMPTM
PT01-Other Symptom 2PRO-CTCAE V1.0OTHER SYMPTOMSAnother symptom 2Another symptom 2Y12015-05-15-P7D129
Symptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCDPT01054CQSSYMPTMSymptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCD
129
PT01055A
PT01083B
QSSYMPTM
PT01-Other Symptom 2 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSMild11Y12015-05-15-P7D130
Symptom TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCDPT01055BQSSYMPTMSymptom TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCD
130
PT01055C
PT01084A
QSSYMPTM
PT01-Other Symptom 3PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D131
Symptom TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCDPT01056AQSSYMPTMSymptom TermSADCRF
STUDYXQS23-P0001QSTESTCD
131
PT01056B
PT01084B
QSSYMPTM
PT01-Other Symptom 3 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D132
Symptom TermSADCRF
STUDYXQS23-P0001QSTESTCDPT01056CQSSYMPTMSymptom TermSADCRF
STUDYXQS23-P0001QSTESTCD
132
PT01057A
PT01085A
QSSYMPTM
PT01-Other
Symptom
4PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D133
TermIRREGULAR PERIODS/VAGINAL BLEEDINGCRF
STUDYXQS23-P0001QSTESTCD
133
PT01058A
PT01085B
QSSYMPTM
PT01-Other
Symptom
4 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D134
TermMISSED EXPECTED MENSTRUAL PERIODCRF
STUDYXQS23-P0001QSTESTCD
134
PT01059A
PT01086A
QSSYMPTM
PT01-Other Symptom 5PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D135
Symptom TermVAGINAL DISCHARGECRF
STUDYXQS23-P0001QSTESTCDPT01060AQSSYMPTMSymptom TermVAGINAL DRYNESSCRF
STUDYXQS23-P0001QSTESTCD
135
PT01061A
PT01086B
QSSYMPTM
PT01-Other Symptom 5 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D136
Symptom TermPAINFUL URINATIONCRF
STUDYXQS23-P0001QSTESTCDPT01062AQSSYMPTMSymptom TermURINARY URGENCYCRF
STUDYXQS23-P0001QSTESTCD
136
PT01062B
PT01087A
QSSYMPTM
PT01-Other Symptom 6PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D137
Symptom TermURINARY URGENCYCRF
STUDYXQS23-P0001QSTESTCD
137
PT01063A
PT01087B
QSSYMPTM
PT01-Other Symptom 6 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D138
Symptom TermURINARY FREQUENCYCRF
STUDYXQS23-P0001QSTESTCDPT01063BQSSYMPTMSymptom TermURINARY FREQUENCYCRF
STUDYXQS23-P0001QSTESTCD
138
PT01064A
PT01088A
QSSYMPTM
PT01-Other
Symptom
7PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D139
TermCHANGE IN USUAL URINE COLORCRF
STUDYXQS23-P0001QSTESTCD
139
PT01065A
PT01088B
QSSYMPTM
PT01-Other
Symptom
7 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D140
TermURINARY INCONTINENCECRF
STUDYXQS23-P0001QSTESTCD
140
PT01065B
PT01089A
QSSYMPTM
PT01-Other Symptom 8PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D141
Symptom TermURINARY INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01066AQSSYMPTMSymptom TermACHIEVE AND MAINTAIN ERECTIONCRF
STUDYXQS23-P0001QSTESTCD
141
PT01067A
PT01089B
QSSYMPTM
PT01-Other Symptom 8 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D142
Symptom TermEJACULATIONCRF
STUDYXQS23-P0001QSTESTCDPT01068AQSSYMPTMSymptom TermDECREASED LIBIDOCRF
STUDYXQS23-P0001QSTESTCD
142
PT01069A
PT01090A
QSSYMPTM
PT01-Other Symptom 9PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D143
Symptom TermDELAYED ORGASMCRF
STUDYXQS23-P0001QSTESTCD
143
PT01070A
PT01090B
QSSYMPTM
PT01-Other Symptom 9 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D144
Symptom TermUNABLE TO HAVE ORGASMCRF
STUDYXQS23-P0001QSTESTCDPT01071AQSSYMPTMSymptom TermPAIN W/SEXUAL INTERCOURSECRF
STUDYXQS23-P0001QSTESTCD
144
PT01072A
PT01091A
QSSYMPTM
PT01-Other Symptom 10PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D145
Symptom TermBREAST SWELLING AND TENDERNESSCRF
STUDYXQS23-P0001QSTESTCDPT01073AQSSYMPTMSymptom TermBRUISINGCRF
STUDYXQS23-P0001
145
QSTESTCD
PT01091BPT01-Other Symptom 10 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D

The suppqs dataset relates the symptom term from the PRO-CTCAE ITEM LIBRARY (Version 1.0) to each symptom item represented in the qs dataset.

CRACKING AT THE CORNERS OF THE MOUTH (CHEILOSIS/CHEILITIS)
PT01074AQSSYMPTMSymptom TermCHILLSCRF
STUDYXQS23-P0001QSTESTCDPT01074BQSSYMPTMSymptom TermCHILLSCRF
STUDYXQS23-P0001QSTESTCDPT01075AQSSYMPTMSymptom TermINCREASED SWEATINGCRF
Dataset wrap
Namesuppqs
QORIG
Dataset2
tableidsuppqs.xpt
STUDYIDRDOMAINUSUBJIDIDVARIDVARVALQNAMQLABELQVAL
STUDYXQS23-P0001QSTESTCD
PT01001A
PT01075BQSSYMPTMSymptom Term
DRY MOUTH
INCREASED SWEATINGCRF
STUDYXQS23-P0001QSTESTCD
PT01002A
PT01076AQSSYMPTMSymptom Term
DIFFICULTY SWALLOWING
DECREASED SWEATINGCRF
STUDYXQS23-P0001QSTESTCD
PT01003A
PT01077AQSSYMPTMSymptom Term
MOUTH/THROAT SORES
HOT FLASHESCRF
STUDYXQS23-P0001QSTESTCD
PT01003B
PT01077BQSSYMPTMSymptom Term
MOUTH/THROAT SORES
HOT FLASHESCRF
STUDYXQS23-P0001QSTESTCD
PT01004A
PT01078AQSSYMPTM
Symptom Term
Symptom TermNOSEBLEEDCRF
STUDYXQS23-P0001QSTESTCD
PT01005A
PT01078BQSSYMPTMSymptom Term
VOICE QUALITY CHANGES
NOSEBLEEDCRF
STUDYXQS23-P0001QSTESTCD
PT01006A
PT01079AQSSYMPTMSymptom Term
HOARSENESS
PAIN AND SWELLING AT INJECTION SITECRF
STUDYXQS23-P0001QSTESTCD
PT01007A
PT01080AQSSYMPTMSymptom Term
TASTE CHANGES
BODY ODORCRF
STUDYXQS23-P0001QSTESTCD
PT01008A
PT01081QSSYMPTMSymptom Term
DECREASED APPETITE
ANY OTHER SYMPTOMS REPORTEDCRF
STUDYXQS23-P0001QSTESTCD
PT01008B
PT01082AQSSYMPTMSymptom Term
DECREASED APPETITE
OTHER SYMPTOM 1CRF
STUDYXQS23-P0001QSTESTCD
PT01009A
PT01082BQSSYMPTMSymptom Term
NAUSEA
OTHER SYMPTOM 1CRF
STUDYXQS23-P0001QSTESTCD
PT01009B
PT01083AQSSYMPTMSymptom Term
NAUSEA
OTHER SYMPTOM 2CRF
STUDYXQS23-P0001QSTESTCD
PT01010A
PT01083BQSSYMPTMSymptom Term
VOMITING
OTHER SYMPTOM 2CRF
STUDYXQS23-P0001QSTESTCD
PT01010B
PT01084AQSSYMPTMSymptom Term
VOMITING
OTHER SYMPTOM 3CRF
STUDYXQS23-P0001QSTESTCD
PT01011A
PT01084BQSSYMPTMSymptom Term
HEARTBURN
OTHER SYMPTOM 3CRF
STUDYXQS23-P0001QSTESTCD
PT01011B
PT01085AQSSYMPTMSymptom Term
HEARTBURN
OTHER SYMPTOM 4CRF
STUDYXQS23-P0001QSTESTCD
PT01012A
PT01085BQSSYMPTMSymptom Term
GAS
OTHER SYMPTOM 4CRF
STUDYXQS23-P0001QSTESTCD
PT01013A
PT01086AQSSYMPTMSymptom Term
BLOATING
OTHER SYMPTOM 5CRF
STUDYXQS23-P0001QSTESTCD
PT01013B
PT01086BQSSYMPTMSymptom Term
BLOATING
OTHER SYMPTOM 5CRF
STUDYXQS23-P0001QSTESTCD
PT01014A
PT01087AQSSYMPTMSymptom Term
HICCUPS
OTHER SYMPTOM 6CRF
STUDYXQS23-P0001QSTESTCD
PT01014B
PT01087BQSSYMPTMSymptom Term
HICCUPS
OTHER SYMPTOM 6CRF
STUDYXQS23-P0001QSTESTCD
PT01015A
PT01088AQSSYMPTMSymptom Term
CONSTIPATION
OTHER SYMPTOM 7CRF
STUDYXQS23-P0001QSTESTCD
PT01016A
PT01088BQSSYMPTMSymptom Term
DIARRHEA
OTHER SYMPTOM 7CRF
STUDYXQS23-P0001QSTESTCD
PT01017A
PT01089AQSSYMPTMSymptom Term
ABDOMINAL PAIN
OTHER SYMPTOM 8CRF
STUDYXQS23-P0001QSTESTCD
PT01017B
PT01089BQSSYMPTMSymptom Term
ABDOMINAL PAIN
OTHER SYMPTOM 8CRF
STUDYXQS23-P0001QSTESTCD
PT01017C
PT01090AQSSYMPTMSymptom Term
ABDOMINAL PAIN
OTHER SYMPTOM 9CRF
STUDYXQS23-P0001QSTESTCD
PT01018A
PT01090BQSSYMPTMSymptom Term
FECAL INCONTINENCE
OTHER SYMPTOM 9CRF
STUDYXQS23-P0001QSTESTCD
PT01018B
PT01091AQSSYMPTMSymptom Term
FECAL INCONTINENCE
OTHER SYMPTOM 10CRF
STUDYXQS23-P0001QSTESTCD
PT01019A
PT01091BQSSYMPTMSymptom Term
SHORTNESS OF BREATH
OTHER SYMPTOM 10CRF
STUDYXQS23-P0001QSTESTCDPT01019BQSSYMPTMSymptom TermSHORTNESS OF BREATHCRFSTUDYXQS23-P0001QSTESTCDPT01020AQSSYMPTMSymptom TermCOUGHCRFSTUDYXQS23-P0001QSTESTCDPT01020BQSSYMPTMSymptom TermCOUGHCRFSTUDYXQS23-P0001QSTESTCDPT01021AQSSYMPTMSymptom TermWHEEZINGCRFSTUDYXQS23-P0001QSTESTCDPT01022AQSSYMPTMSymptom TermSWELLINGCRF